Clinical Trial Update: Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of Evixapodlin (formerly GS-4224) in participants with advanced solid tumors was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Evixapodlin (Evixapodlin)

Snippet

Sponsor: Gilead Sciences | Conditions: Advanced Solid Tumors | Phase 1 | Status: TERMINATED | Results posted: 2022-08-10